2023 World Conference on Lung Cancer (Posters)-EP06.02. Agreement among Programmed Cell Death Ligand-1 Immunohistochemistry Results Using 73-10, 22C3 and 28-8 Antibodies for Lung Cancer.

EP06.02. Agreement among Programmed Cell Death Ligand-1 Immunohistochemistry Results Using 73-10, 22C3 and 28-8 Antibodies for Lung Cancer. - PDF(Abstract)

Back to course

Pdf Summary

This research study aimed to investigate the agreement among three different immunohistochemistry assays (Dako 73-10, 22C3, and 28-8) for detecting programmed cell death ligand-1 (PD-L1) in non-small cell lung cancer (NSCLC). The study utilized surgical specimens from 420 NSCLC patients and assessed PD-L1 expression using the 73-10 assay. The results were compared to the previously used 22C3 and 28-8 assays.<br /><br />The findings revealed that the agreement between the 73-10 assay and the 22C3 assay was high, with an overall positive agreement (OPA) of 84.1% at a 1% PD-L1 cutoff. The OPA between the 73-10 and 28-8 assays was also high, at 87.7% at a 1% PD-L1 cutoff. However, when comparing the 28-8 assay to the 73-10 assay, the positive agreement (PPA) decreased to 83.3% at a 1% PD-L1 cutoff.<br /><br />The study concluded that there was high agreement between the 73-10 assay and both the 22C3 and 28-8 assays, suggesting that the results of the 73-10 assay could be translated into those of either the 22C3 or 28-8 assays. Additionally, the results indicated that the 22C3 assay results could be translated to those of the 73-10 assay. However, the results of the 28-8 assay could not be translated to those of the 73-10 assay.<br /><br />Overall, this research provides valuable information regarding the agreement among different PD-L1 immunohistochemistry assays for NSCLC. The findings suggest that the 73-10 assay may be a reliable and interchangeable alternative to the 22C3 assay for assessing PD-L1 expression in NSCLC patients.

Asset Subtitle

Tomohito Saito

Meta Tag

Speaker Tomohito Saito

Topic Pathology & Biomarkers: Biomarkers for Immuno-oncology

Keywords

immunohistochemistry assays

Dako 73-10

22C3

28-8

programmed cell death ligand-1

PD-L1

non-small cell lung cancer

NSCLC

surgical specimens

positive agreement